|
1
|
Kilfoy BA, Zheng T, Holford TR, Han X,
Ward MH, Sjodin A, Zhang Y, Bai Y, Zhu C, Guo GL, et al:
International patterns and trends in thyroid cancer incidence,
1973–2002. Cancer Causes Control. 20:525–531. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xiang J, Wu Y, Li DS, Shen Q, Wang ZY, Sun
TQ, An Y and Guan Q: New clinical features of thyroid cancer in
eastern China. J Visc Surg. 147:e53–e56. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Noguchi S, Noguchi A and Murakami N:
Papillary carcinoma of the thyroid. I. Developing pattern of
metastasis. Cancer. 26:1053–1060. 1970. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mazzaferri EL and Jhiang SM: Long-term
impact of initial surgical and medical therapy on papillary and
follicular thyroid cancer. Am J Med. 97:418–428. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hundahl SA, Cady B, Cunningham MP,
Mazzaferri E, McKee RF, Rosai J, Shah JP, Fremgen AM, Stewart AK
and Hölzer S: Initial results from a prospective cohort study of
5583 cases of thyroid carcinoma treated in the united states during
1996. U.S. and German Thyroid Cancer Study Group. An American
College of Surgeons Commission on Cancer Patient Care Evaluation
study. Cancer. 89:202–217. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Patron V, Bedfert C, Le Clech G, Aubry K
and Jegoux F: Pattern of lateral neck metastases in N0 papillary
thyroid carcinoma. BMC Cancer. 11:82011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xing M: BRAF mutation in thyroid cancer.
Endocr Relat Cancer. 12:245–262. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
da Silva RC, de Paula HS, Leal CB, Cunha
BC, de Paula EC, Alencar RC, Meneghini AJ, Silva AM, Gontijo AP,
Wastowski IJ, et al: BRAF overexpression is associated with
BRAFV600E mutation in papillary thyroid carcinomas. Genet Mol Res.
14:5065–5075. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schulten HJ, Alotibi R, Al-Ahmadi A, Ata
M, Karim S, Huwait E, Gari M, Al-Ghamdi K, Al-Mashat F, Al-Hamour
O, et al: Effect of BRAF mutational status on expression profiles
in conventional papillary thyroid carcinomas. BMC Genomics. 16
Suppl 1:S62015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xing M, Alzahrani AS, Carson KA, Shong YK,
Kim TY, Viola D, Elisei R, Bendlová B, Yip L, Mian C, et al:
Association between BRAFV600E mutation and recurrence of papillary
thyroid cancer. J Clin Oncol. 33:42–50. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yarchoan M, LiVolsi VA and Brose MS: BRAF
mutation and thyroid cancer recurrence. J Clin Oncol. 33:7–8. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jones PA and Baylin SB: The epigenomics of
cancer. Cell. 128:683–692. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kondo Y and Issa JP: DNA methylation
profiling in cancer. Expert Rev Mol Med. 12:e232010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Baylin SB and Ohm JE: Epigenetic gene
silencing in cancer - a mechanism for early oncogenic pathway
addiction? Nat Rev Cancer. 6:107–116. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jaenisch R and Bird A: Epigenetic
regulation of gene expression: How the genome integrates intrinsic
and environmental signals. Nat Genet. 33 Suppl:S245–S254. 2003.
View Article : Google Scholar
|
|
16
|
Schweppe RE, Klopper JP, Korch C,
Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland
JA, Smallridge RC, et al: Deoxyribonucleic acid profiling analysis
of 40 human thyroid cancer cell lines reveals cross-contamination
resulting in cell line redundancy and misidentification. J Clin
Endocrinol Metab. 93:4331–4341. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yu J, Zhang HY, Ma ZZ, Lu W, Wang YF and
Zhu JD: Methylation profiling of twenty four genes and the
concordant methylation behaviours of nineteen genes that may
contribute to hepatocellular carcinogenesis. Cell Res. 13:319–333.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Weisenberger DJ, Campan M, Long TI, Kim M,
Woods C, Fiala E, Ehrlich M and Laird PW: Analysis of repetitive
element DNA methylation by MethyLight. Nucleic Acids Res.
33:6823–6836. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xing M: Gene methylation in thyroid
tumorigenesis. Endocrinology. 148:948–953. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Samowitz WS, Albertsen H, Sweeney C,
Herrick J, Caan BJ, Anderson KE, Wolff RK and Slattery ML:
Association of smoking, CpG island methylator phenotype, and V600E
BRAF mutations in colon cancer. J Natl Cancer Inst. 98:1731–1738.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hou P, Ji M and Xing M: Association of
PTEN gene methylation with genetic alterations in the
phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid
tumors. Cancer. 113:2440–2447. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Porra V, Ferraro-Peyret C, Durand C,
Selmi-Ruby S, Giroud H, Berger-Dutrieux N, Decaussin M, Peix JL,
Bournaud C, Orgiazzi J, et al: Silencing of the tumor suppressor
gene SLC5A8 is associated with BRAF mutations in classical
papillary thyroid carcinomas. J Clin Endocrinol Metab.
90:3028–3035. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lance-Jones C, Omelchenko N, Bailis A,
Lynch S and Sharma K: Hoxd10 induction and regionalization in the
developing lumbosacral spinal cord. Development. 128:2255–2268.
2001.PubMed/NCBI
|
|
24
|
Gurnett CA, Keppel C, Bick J, Bowcock AM
and Dobbs MB: Absence of HOXD10 mutations in idiopathic clubfoot
and sporadic vertical talus. Clin Orthop Relat Res. 462:27–31.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Samuel S and Naora H: Homeobox gene
expression in cancer: Insights from developmental regulation and
deregulation. Eur J Cancer. 41:2428–2437. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shah N and Sukumar S: The Hox genes and
their roles in oncogenesis. Nat Rev Cancer. 10:361–371. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Botas J: Control of morphogenesis and
differentiation by HOM/Hox genes. Curr Opin Cell Biol. 5:1015–1022.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jung C, Kim RS, Zhang H, Lee SJ, Sheng H,
Loehrer PJ, Gardner TA, Jeng MH and Kao C: HOXB13 is downregulated
in colorectal cancer to confer TCF4-mediated transactivation. Br J
Cancer. 92:2233–2239. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Raman V, Martensen SA, Reisman D, Evron E,
Odenwald WF, Jaffee E, Marks J and Sukumar S: Compromised HOXA5
function can limit p53 expression in human breast tumours. Nature.
405:974–978. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Friedmann Y, Daniel CA, Strickland P and
Daniel CW: Hox genes in normal and neoplastic mouse mammary gland.
Cancer Res. 54:5981–5985. 1994.PubMed/NCBI
|
|
31
|
Rauch T, Wang Z, Zhang X, Zhong X, Wu X,
Lau SK, Kernstine KH, Riggs AD and Pfeifer GP: Homeobox gene
methylation in lung cancer studied by genome-wide analysis with a
microarray-based methylated CpG island recovery assay. Proc Natl
Acad Sci USA. 104:pp. 5527–5532. 2007; View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shiraishi M, Sekiguchi A, Terry MJ, Oates
AJ, Miyamoto Y, Chuu YH, Munakata M and Sekiya T: A comprehensive
catalog of CpG islands methylated in human lung adenocarcinomas for
the identification of tumor suppressor genes. Oncogene.
21:3804–3813. 2002. View Article : Google Scholar : View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shiraishi M, Sekiguchi A, Oates AJ, Terry
MJ and Miyamoto Y: HOX gene clusters are hotspots of de novo
methylation in CpG islands of human lung adenocarcinomas. Oncogene.
21:3659–3662. 2002. View Article : Google Scholar : View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Carrio M, Arderiu G, Myers C and Boudreau
NJ: Homeobox D10 induces phenotypic reversion of breast tumor cells
in a three-dimensional culture model. Cancer Res. 65:7177–7185.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vardhini NV, Rao PJ, Murthy PB and
Sudhakar G: HOXD10 expression in human breast cancer. Tumour Biol.
35:10855–10860. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sekar P, Bharti JN, Nigam JS, Sharma A and
Soni PB: Evaluation of p53, HoxD10, and E-Cadherin status in breast
cancer and correlation with histological grade and other prognostic
factors. J Oncol. 702527:20142014.
|
|
37
|
Hakami F, Darda L, Stafford P, Woll P,
Lambert DW and Hunter KD: The roles of HOXD10 in the development
and progression of head and neck squamous cell carcinoma (HNSCC).
Br J Cancer. 111:807–816. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Myers C, Charboneau A, Cheung I, Hanks D
and Boudreau N: Sustained expression of homeobox D10 inhibits
angiogenesis. Am J Pathol. 161:2099–2109. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang L, Chen S, Xue M, Zhong J, Wang X,
Gan L, Lam EK, Liu X, Zhang J, Zhou T, et al: Homeobox D10 gene, a
candidate tumor suppressor, is downregulated through promoter
hypermethylation and associated with gastric carcinogenesis. Mol
Med. 18:389–400. 2012. View Article : Google Scholar : View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yang H, Zhou J, Mi J, Ma K, Fan Y, Ning J,
Wang C, Wei X, Zhao H and Li E: HOXD10 acts as a tumor-suppressive
factor via inhibition of the RHOC/AKT/MAPK pathway in human
cholangiocellular carcinoma. Oncol Rep. 34:1681–1691. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Baek SK, Jung KY, Kang SM, Kwon SY, Woo
JS, Cho SH and Chung EJ: Clinical risk factors associated with
cervical lymph node recurrence in papillary thyroid carcinoma.
Thyroid. 20:147–152. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wada N, Masudo K, Nakayama H, Suganuma N,
Matsuzu K, Hirakawa S, Rino Y, Masuda M and Imada T: Clinical
outcomes in older or younger patients with papillary thyroid
carcinoma: Impact of lymphadenopathy and patient age. Eur J Surg
Oncol. 34:202–207. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ito Y, Hirokawa M, Jikuzono T, Higashiyama
T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K and
Miyauchi A: Extranodal tumor extension to adjacent organs predicts
a worse cause-specific survival in patients with papillary thyroid
carcinoma. World J Surg. 31:1194–1201. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Oh CM, Jung KW, Won YJ, Shin A, Kong HJ
and Lee JS: Age-period-cohort analysis of thyroid cancer incidence
in Korea. Cancer Res Treat. 47:362–369. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Park KS, Oh YL, Ki CS and Kim JW:
Evaluation of the Real-Q BRAFV600E detection assay in fine-needle
aspiration samples of thyroid nodules. J Mol Diagn. 17:431–437.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zou M, Baitei EY, Alzahrani AS, BinHumaid
FS, Alkhafaji D, Al-Rijjal RA, Meyer BF and Shi Y: Concomitant RAS
RET/PTC, or BRAF mutations in advanced stage of papillary thyroid
carcinoma. Thyroid. 24:1256–1266. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hwang TS, Kim WY, Han HS, Lim SD, Kim WS,
Yoo YB, Park KS, Oh SY, Kim SK and Yang JH: Preoperative RAS
mutational analysis is of great value in predicting follicular
variant of papillary thyroid carcinoma. Biomed Res Int.
2015:6970682015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Armstrong MJ, Yang H, Yip L, Ohori NP,
McCoy KL, Stang MT, Hodak SP, Nikiforova MN, Carty SE and Nikiforov
YE: PAX8/PPARγ rearrangement in thyroid nodules predicts
follicular-pattern carcinomas, in particular the encapsulated
follicular variant of papillary carcinoma. Thyroid. 24:1369–1374.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Gómez Sáez JM: Diagnostic and prognostic
markers in differentiated thyroid cancer. Curr Genomics.
12:597–608. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hoque MO, Rosenbaum E, Westra WH, Xing M,
Ladenson P, Zeiger MA, Sidransky D and Umbricht CB: Quantitative
assessment of promoter methylation profiles in thyroid neoplasms. J
Clin Endocrinol Metab. 90:4011–4018. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Hu S, Ewertz M, Tufano RP, Brait M,
Carvalho AL, Liu D, Tufaro AP, Basaria S, Cooper DS, Sidransky D,
et al: Detection of serum deoxyribonucleic acid methylation
markers: A novel diagnostic tool for thyroid cancer. J Clin
Endocrinol Metab. 91:98–104. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Smith JA, Fan CY, Zou C, Bodenner D and
Kokoska MS: Methylation status of genes in papillary thyroid
carcinoma. Arch Otolaryngol Head Neck Surg. 133:1006–1011. 2007.
View Article : Google Scholar : PubMed/NCBI
|
